Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
- Conditions
- Metastatic Colorectal Cancer or Head and Neck Squamous Cell CarcinomaCetuximab-induced Papulopustular (Acneiform) Rash Who Have
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01931150
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT01920737
- Locations
- 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma (MM)
- Interventions
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT01919086
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01916109
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Quit IT: Development of a Web-based, 3D Coping Skills Game to Increase Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization
- Conditions
- Tobacco Use Cessation
- Interventions
- Other: web-based video game (Quit IT)Behavioral: QuestionnairesBehavioral: Evaluation Interview
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01915836
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
- Conditions
- SarcomaMelanomaCarcinomaMyelomaLymphoma
- Interventions
- Radiation: [18F]-SKI-249380Procedure: PET/CT scanOther: Blood draws
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01916135
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
- Conditions
- Breast Cancer
- Interventions
- Drug: Fluorestradiol (FES)Procedure: PET/CT Imaging
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT01916122
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
- Conditions
- Esophageal CancerGastric Cancer
- Interventions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT01913639
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients
- Conditions
- Advanced Gastrointestinal Cancer
- Interventions
- Behavioral: single pilot interviewBehavioral: usual careBehavioral: goals-of-care (GOC) videoBehavioral: goals-of-care (GOC) video and narrative questionBehavioral: Part 2
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 178
- Registration Number
- NCT01912131
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
- Conditions
- T Cell Non-Hodgkin Lymphoma
- Interventions
- Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01908777
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States